{"preliminary_commentary":{"by_channel":{"x_thread":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"RIVER PDAC","nct_id":"NCT06989437","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=river-pdac-nct06989437. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"ponsegromab 200 mg subcutaneous injection every 4 weeks","label":"Double-Blind ponsegromab Treatment lower dose","type":"EXPERIMENTAL"},{"description":"ponsegromab 400 mg subcutaneous injection every 4 weeks","label":"Double-Blind ponsegromab Treatment higher dose","type":"EXPERIMENTAL"},{"description":"Match placebo subcutaneous injection every 4 weeks","label":"Double-Blind Placebo Treatment","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-12-24","type":"ESTIMATED"},"conditions":["Cachexia","Metastatic Pancreatic Ductal Adenocarcinoma"],"enrollment":{"count":982,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"ponsegromab","otherNames":[],"type":"DRUG"},{"name":"placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-14","lead_sponsor":"Pfizer","official_title":"A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background First-Line Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma","overall_status":"RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2028-01-23","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Percent change from baseline in body weight for ponsegromab compared to placebo","timeFrame":"Baseline, Week 12"},{"measure":"Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy 5-item Anorexia Symptom Scale scores","timeFrame":"Baseline, Week 12"}],"references":[],"start_date":{"date":"2025-10-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue","url":"https://clinicaltrials.gov/study/NCT06989437"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/river-pdac-nct06989437"}